Pharmaceutical News

RSS

Simple placebo pill can track footprints of prior antidepressant use

Individuals with major depressive disorder (MDD) often undergo multiple courses of antidepressant treatment during their lives. This is because the disorder can recur despite treatment and because finding the right medication for a specific individual can take time.

27 Mar 2012

UC professor to show new anticancer agent at ACS Spring 2012 meeting

Advances in chemotherapy have dramatically improved the outlook for many cancer patients, but the side effects of this treatment are daunting. A new generation of chemotherapy drugs with fewer side effects is the goal of Edward J. Merino, assistant professor of chemistry at the University of Cincinnati.

27 Mar 2012

Hapten licenses HPT-721 to prevent poison ivy dermatitis

Hapten Sciences Inc. of Memphis, Tenn., has licensed a compound developed by ElSohly Laboratories Inc. and University of Mississippi pharmaceutical researchers to prevent reactions to poison ivy, oak and sumac.

27 Mar 2012

Pharmaplan, Moberg Derma to distribute Nalox/Emtrix in South Africa

Moberg Derma AB has entered into a distribution agreement with Pharmaplan (Pty) Ltd. for Nalox//Emtrix - for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis.

27 Mar 2012

Scientist develops a way to encase nutraceuticals in food-based products

A Purdue University food scientist has developed a way to encase nutritional supplements in food-based products so that one day consumers might be able to sprinkle vitamins, antioxidants and other beneficial compounds right onto their meals.

27 Mar 2012

Intravenous immune globulin effective treatment for GBS, CIDP

Intravenous immune globulin (IVIg) is an effective treatment for certain disorders of the nerve and muscles, including Guillain-Barré syndrome (GBS) and a form of neuropathy called chronic inflammatory demyelinating polyneuropathy (CIDP), according to a guideline issued by the American Academy of Neurology.

27 Mar 2012

Study clarifies conflicting reports for clot aspiration and abciximab administration

The anti-platelet drug abciximab, delivered directly to lesions caused by a heart attack, significantly decreased damage to the heart muscle in high-risk patients while clot aspiration showed no impact, according to research presented today at the American College of Cardiology's 61st Annual Scientific Session.

From Medtronic 27 Mar 2012

FDA issues Complete Response letter to MAP's NDA for LEVADEX

MAP Pharmaceuticals, Inc. today announced that the United States Food and Drug Administration (FDA) has issued a Complete Response letter to its New Drug Application (NDA) for LEVADEX (dihydroergotamine) inhalation aerosol.

27 Mar 2012

Viewpoints: Law on generic drugs is 'outrageous denial' of patients' rights; Could Romney be the best spokesman against federal law?

Dozens of suits against drug companies have been dismissed in federal and state courts because of a decision by the Supreme Court last year that makes it virtually impossible to sue generic manufacturers for failing to provide adequate warning of a prescription drug's dangers. This outrageous denial of a patient's right to recover fair damages makes it imperative that Congress or the Food and Drug Administration fashion a remedy.

27 Mar 2012

1 in 5 Australians have taken an expired medicine

NPS is urging all Australians to clean out their medicine cabinets today as part of national Be Medicinewise Week 2012. New research from NPS found around 1 in 5 people reported ever having taken an expired medicine.

26 Mar 2012

USANA Health Sciences expands into French and Belgium markets

USANA Health Sciences, Inc., a global nutritional supplements company, today announced the official opening of its France and Belgium markets. Bringing the company's international expansion to 18 countries worldwide, USANA's newest office will reside on the Champs-Elysees in Paris and will initially offer seven nutritional supplements and eight skin-care products.

26 Mar 2012

EMA accepts Arena's lorcaserin MAA for weight control

Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.

26 Mar 2012

FDA approves Teva's QNASL nasal aerosol corticosteroid

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration has approved QNASL Nasal Aerosol, a new, "dry" nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

26 Mar 2012

AstraZeneca's lawsuit against FDA dismissed without prejudice

AstraZeneca today announced that on March 23, 2012 the US District Court for the District of Columbia issued an opinion and order in AstraZeneca's lawsuit against the US Food and Drug Administration regarding final marketing approval of generic quetiapine. The Court denied the Company's request for a preliminary injunction and dismissed the lawsuit without prejudice.

26 Mar 2012

Hypertension treatment fails to improve in the former Soviet Union

New research has found that treatment of hypertension has failed to improve in the last decade in the countries of the former Soviet Union. Hypertension, or high blood pressure, is one of the leading causes of avoidable deaths in the former Soviet Union.

26 Mar 2012

TOLMAR, Impax Labs partner for alternative dosage form products

Impax Laboratories, Inc. and TOLMAR, Inc. today announced that they will collaborate on a multiproduct agreement for the development, supply and distribution of alternative dosage form products.

26 Mar 2012

OSI Systems receives FDA clearance for Arkon anesthesia delivery system

OSI Systems, Inc., a vertically-integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that its Healthcare division, Spacelabs Healthcare, received clearance under Section 510(k) from the U.S. Food and Drug Administration to market the Arkon high-performance anesthesia delivery system.

26 Mar 2012

Rifaximin and lubiprostone offer best options for patients with IBS

Cedars-Sinai researchers have determined that two prevalent drug therapies - rifaximin and lubiprostone - offer some of the best options for treating irritable bowel syndrome, a widespread disorder that affects up to one in five Americans.

26 Mar 2012

USPTO issues patent to Inovio's SynCon H1N1 influenza vaccine

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,133,723, covering Inovio's SynCon universal vaccine related to H1N1 influenza.

26 Mar 2012

Bacteriophages can tackle drug-resistant bacterial infections

Viruses that can target and destroy bacteria have the potential to be an effective strategy for tackling hard-to-treat bacterial infections. The development of such novel therapies is being accelerated in response to growing antibiotic resistance, says Dr David Harper at the Society for General Microbiology's Spring Conference in Dublin.

26 Mar 2012